Steven RPh - Transgene VP Officer
| TRGNF Stock | USD 1.00 0.00 0.00% |
Insider
Steven RPh is VP Officer of Transgene SA
| Age | 61 |
| Phone | 33 3 88 27 91 00 |
| Web | https://www.transgene.fr |
Transgene Management Efficiency
The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ana Limon | Oryzon Genomics SA | N/A | |
| Jean Epinat | Cellectis SA | N/A | |
| Stefanie Magner | Genfit SA | 42 | |
| Gerard MD | Mayne Pharma Group | N/A | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| MSc MSc | Cellectis SA | 54 | |
| Thomas Baetz | Genfit SA | 49 | |
| Dr JD | Silence Therapeutics plc | 63 | |
| Pascal Prigent | Genfit SA | 55 | |
| Marie Lindholm | Silence Therapeutics plc | N/A | |
| Carlos Arjol | Oryzon Genomics SA | N/A | |
| Shengfei Fang | Immutep Limited | N/A | |
| Jrgen Wittendorff | Silence Therapeutics plc | N/A | |
| Aaron Gray | Mayne Pharma Group | N/A | |
| Xavier Ribera | Oryzon Genomics SA | N/A | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| Pr Staels | Genfit SA | 60 | |
| Kimberly JD | Mayne Pharma Group | N/A | |
| Giles MD | Silence Therapeutics plc | 69 | |
| JeanChristophe Marcoux | Genfit SA | 46 | |
| Jordi Pey | Oryzon Genomics SA | N/A | |
Management Performance
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 |
Transgene SA Leadership Team
Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maud MD, VP Officer | ||
| Eric Quemeneur, Executive Vice President Vice President - Research & Development, Member of the Management Committee | ||
| Gaelle Stadtler, VP HR | ||
| JeanPhilippe Del, Vice President - Finance, Member of the Management Committee | ||
| Elisabetta Castelli, Director of Investor Relations | ||
| Hedi Brahim, CEO Director | ||
| Lucie Larguier, Director IR | ||
| Steven RPh, VP Officer | ||
| LLM JD, Gen VP | ||
| Philippe Slos, Head Laboratory |
Transgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 152.15 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | (7.42) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 10.71 X |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.